Home/MediMabBio/Kwanghyun Kim
KK

Kwanghyun Kim

CFO

MediMabBio

MediMabBio Pipeline

DrugIndicationPhase
aTIGIT-IL15 Fusion AntibodyOncologyPre-clinical